Robert Wolfe
Concepts (643)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Muscle Proteins | 90 | 2024 | 320 | 14.520 |
Why?
| Muscle, Skeletal | 111 | 2024 | 784 | 13.670 |
Why?
| Dietary Proteins | 51 | 2025 | 252 | 13.230 |
Why?
| Amino Acids, Essential | 49 | 2024 | 133 | 10.320 |
Why?
| Amino Acids | 62 | 2025 | 373 | 9.150 |
Why?
| Protein Biosynthesis | 28 | 2021 | 232 | 5.180 |
Why?
| Dietary Supplements | 33 | 2024 | 449 | 4.320 |
Why?
| Nutritional Requirements | 18 | 2025 | 68 | 4.180 |
Why?
| Burns | 28 | 2022 | 165 | 4.110 |
Why?
| Exercise | 29 | 2024 | 516 | 3.450 |
Why?
| Aging | 27 | 2020 | 694 | 3.380 |
Why?
| Diet | 16 | 2024 | 568 | 3.370 |
Why?
| Phenylalanine | 49 | 2022 | 134 | 3.320 |
Why?
| Triglycerides | 18 | 2020 | 160 | 3.290 |
Why?
| Sarcopenia | 10 | 2022 | 95 | 3.010 |
Why?
| Proteins | 15 | 2022 | 339 | 2.990 |
Why?
| Milk Proteins | 10 | 2016 | 77 | 2.960 |
Why?
| Isotopes | 6 | 2022 | 23 | 2.910 |
Why?
| Insulin | 39 | 2024 | 467 | 2.690 |
Why?
| Meals | 13 | 2024 | 62 | 2.650 |
Why?
| Glucose | 18 | 2022 | 341 | 2.560 |
Why?
| Insulin Resistance | 19 | 2024 | 268 | 2.500 |
Why?
| Humans | 216 | 2025 | 50516 | 2.260 |
Why?
| Bed Rest | 15 | 2020 | 36 | 2.120 |
Why?
| Leucine | 14 | 2023 | 117 | 2.120 |
Why?
| Body Composition | 27 | 2022 | 327 | 2.060 |
Why?
| Anabolic Agents | 7 | 2019 | 39 | 2.030 |
Why?
| Digestion | 5 | 2020 | 29 | 2.020 |
Why?
| Kinetics | 31 | 2022 | 623 | 1.950 |
Why?
| Energy Intake | 11 | 2024 | 176 | 1.940 |
Why?
| Liver | 12 | 2021 | 1132 | 1.920 |
Why?
| Male | 147 | 2024 | 25913 | 1.920 |
Why?
| Blood Glucose | 30 | 2020 | 447 | 1.840 |
Why?
| Skin | 10 | 2015 | 389 | 1.800 |
Why?
| Aged | 66 | 2024 | 9743 | 1.680 |
Why?
| Energy Metabolism | 19 | 2024 | 286 | 1.680 |
Why?
| Feeding Behavior | 8 | 2024 | 185 | 1.650 |
Why?
| Weight Loss | 6 | 2018 | 245 | 1.580 |
Why?
| Resistance Training | 11 | 2024 | 100 | 1.580 |
Why?
| Obesity | 14 | 2024 | 1121 | 1.540 |
Why?
| Nutrition Policy | 7 | 2012 | 39 | 1.520 |
Why?
| Rabbits | 22 | 2015 | 372 | 1.500 |
Why?
| Female | 114 | 2024 | 27086 | 1.470 |
Why?
| Palmitates | 7 | 2022 | 27 | 1.470 |
Why?
| Animals | 54 | 2024 | 13124 | 1.450 |
Why?
| Adult | 80 | 2024 | 13584 | 1.380 |
Why?
| Muscle Strength | 13 | 2024 | 127 | 1.360 |
Why?
| Carbon Isotopes | 22 | 2017 | 70 | 1.330 |
Why?
| Lipid Metabolism | 7 | 2020 | 175 | 1.330 |
Why?
| Leg | 21 | 2011 | 123 | 1.300 |
Why?
| Arginine | 9 | 2022 | 187 | 1.300 |
Why?
| Postprandial Period | 11 | 2024 | 72 | 1.290 |
Why?
| Hyperinsulinism | 6 | 2015 | 27 | 1.280 |
Why?
| Wound Healing | 6 | 2008 | 186 | 1.270 |
Why?
| Models, Biological | 13 | 2024 | 716 | 1.210 |
Why?
| Dietary Carbohydrates | 11 | 2024 | 91 | 1.200 |
Why?
| Double-Blind Method | 17 | 2021 | 708 | 1.200 |
Why?
| Fatty Acids, Nonesterified | 10 | 2020 | 39 | 1.190 |
Why?
| Heart Failure | 3 | 2019 | 528 | 1.140 |
Why?
| Wounds and Injuries | 6 | 2008 | 287 | 1.060 |
Why?
| Food, Formulated | 4 | 2019 | 42 | 1.040 |
Why?
| Hypoglycemic Agents | 7 | 2013 | 173 | 1.020 |
Why?
| Middle Aged | 60 | 2024 | 12613 | 1.000 |
Why?
| Valerates | 3 | 2017 | 38 | 0.950 |
Why?
| Isotope Labeling | 4 | 2019 | 54 | 0.940 |
Why?
| Critical Illness | 8 | 2016 | 302 | 0.940 |
Why?
| Overweight | 4 | 2018 | 215 | 0.870 |
Why?
| Swine | 8 | 2019 | 408 | 0.860 |
Why?
| Cross-Over Studies | 13 | 2022 | 228 | 0.850 |
Why?
| Pyruvic Acid | 3 | 2021 | 21 | 0.830 |
Why?
| Amino Acids, Branched-Chain | 3 | 2017 | 42 | 0.810 |
Why?
| Hyperglycemia | 6 | 2020 | 81 | 0.800 |
Why?
| Mitochondria, Muscle | 6 | 2024 | 37 | 0.790 |
Why?
| Nitric Oxide | 4 | 2015 | 259 | 0.770 |
Why?
| Geriatric Assessment | 2 | 2021 | 116 | 0.770 |
Why?
| Whole Body Imaging | 2 | 2019 | 26 | 0.740 |
Why?
| Food Analysis | 1 | 2021 | 26 | 0.740 |
Why?
| Kidney | 2 | 2021 | 696 | 0.730 |
Why?
| Deuterium | 11 | 2019 | 45 | 0.730 |
Why?
| Gluconeogenesis | 1 | 2020 | 4 | 0.730 |
Why?
| Lipoproteins, VLDL | 4 | 2024 | 9 | 0.720 |
Why?
| Lactic Acid | 2 | 2021 | 75 | 0.720 |
Why?
| Actinidia | 1 | 2020 | 7 | 0.710 |
Why?
| Young Adult | 18 | 2024 | 4107 | 0.710 |
Why?
| Glycolysis | 1 | 2021 | 69 | 0.700 |
Why?
| Hydrocortisone | 8 | 2020 | 110 | 0.700 |
Why?
| Muscular Atrophy | 4 | 2021 | 71 | 0.680 |
Why?
| Aged, 80 and over | 13 | 2021 | 3227 | 0.680 |
Why?
| Food, Fortified | 2 | 2021 | 27 | 0.670 |
Why?
| Caloric Restriction | 3 | 2020 | 35 | 0.660 |
Why?
| Muscle Contraction | 5 | 2019 | 112 | 0.660 |
Why?
| Renal Dialysis | 9 | 2015 | 171 | 0.660 |
Why?
| Metformin | 3 | 2005 | 65 | 0.650 |
Why?
| Elder Nutritional Physiological Phenomena | 2 | 2015 | 7 | 0.630 |
Why?
| Human Growth Hormone | 2 | 2017 | 50 | 0.630 |
Why?
| Nutritional Status | 6 | 2021 | 136 | 0.620 |
Why?
| Stress, Physiological | 4 | 2019 | 171 | 0.620 |
Why?
| DNA | 4 | 2007 | 535 | 0.620 |
Why?
| Beverages | 4 | 2019 | 56 | 0.610 |
Why?
| Regional Blood Flow | 10 | 2015 | 109 | 0.610 |
Why?
| Sepsis | 6 | 2019 | 225 | 0.600 |
Why?
| Muscle Cells | 4 | 2009 | 22 | 0.600 |
Why?
| Adrenergic beta-Antagonists | 5 | 2006 | 108 | 0.600 |
Why?
| Diabetes Mellitus | 2 | 2020 | 279 | 0.600 |
Why?
| Critical Care | 2 | 2017 | 214 | 0.580 |
Why?
| Lipids | 7 | 2022 | 152 | 0.570 |
Why?
| Glucose Intolerance | 4 | 2020 | 27 | 0.570 |
Why?
| Cardiovascular Diseases | 4 | 2021 | 460 | 0.560 |
Why?
| Fenofibrate | 2 | 2007 | 16 | 0.560 |
Why?
| Hypolipidemic Agents | 2 | 2007 | 28 | 0.560 |
Why?
| Chromatography, High Pressure Liquid | 4 | 2007 | 326 | 0.560 |
Why?
| Time Factors | 19 | 2021 | 2935 | 0.550 |
Why?
| Eating | 9 | 2024 | 158 | 0.550 |
Why?
| Skin Transplantation | 3 | 2007 | 43 | 0.540 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 3 | 2005 | 60 | 0.530 |
Why?
| Kidney Failure, Chronic | 7 | 2015 | 201 | 0.520 |
Why?
| Fatty Acids | 6 | 2013 | 144 | 0.520 |
Why?
| Adolescent | 24 | 2024 | 6446 | 0.520 |
Why?
| Weight Lifting | 3 | 2004 | 29 | 0.510 |
Why?
| Homeostasis | 3 | 2014 | 204 | 0.510 |
Why?
| Proteolysis | 5 | 2020 | 96 | 0.500 |
Why?
| Cardiovascular Agents | 1 | 2015 | 55 | 0.490 |
Why?
| Citrulline | 1 | 2015 | 102 | 0.480 |
Why?
| Diet, Reducing | 1 | 2015 | 37 | 0.480 |
Why?
| Epidermis | 2 | 2006 | 23 | 0.470 |
Why?
| Metabolomics | 1 | 2016 | 135 | 0.470 |
Why?
| Nutritional Support | 1 | 2014 | 35 | 0.470 |
Why?
| Zinc | 2 | 2022 | 52 | 0.460 |
Why?
| Testosterone | 5 | 2007 | 145 | 0.460 |
Why?
| Ileum | 3 | 2019 | 85 | 0.460 |
Why?
| Adipose Tissue | 4 | 2013 | 192 | 0.450 |
Why?
| Protein Stability | 2 | 2017 | 43 | 0.450 |
Why?
| Meat | 4 | 2024 | 60 | 0.450 |
Why?
| Gas Chromatography-Mass Spectrometry | 4 | 2016 | 68 | 0.450 |
Why?
| Administration, Oral | 9 | 2009 | 434 | 0.440 |
Why?
| Up-Regulation | 1 | 2015 | 446 | 0.440 |
Why?
| Radiopharmaceuticals | 1 | 2014 | 204 | 0.430 |
Why?
| Nitrogen Isotopes | 7 | 2022 | 38 | 0.430 |
Why?
| Biological Availability | 4 | 2019 | 102 | 0.420 |
Why?
| Muscle Development | 1 | 2013 | 22 | 0.420 |
Why?
| PPAR alpha | 3 | 2007 | 56 | 0.420 |
Why?
| Infusions, Intravenous | 9 | 2021 | 213 | 0.410 |
Why?
| Frail Elderly | 1 | 2012 | 33 | 0.410 |
Why?
| Body Mass Index | 13 | 2022 | 677 | 0.410 |
Why?
| Activities of Daily Living | 2 | 2014 | 177 | 0.400 |
Why?
| Biopsy | 9 | 2011 | 588 | 0.400 |
Why?
| Palmitoyl Coenzyme A | 4 | 2015 | 4 | 0.400 |
Why?
| Fibroblasts | 2 | 2004 | 336 | 0.390 |
Why?
| Glutamine | 2 | 2003 | 175 | 0.390 |
Why?
| Glycerol | 4 | 2009 | 15 | 0.380 |
Why?
| Mitochondria | 4 | 2024 | 399 | 0.380 |
Why?
| Oxidation-Reduction | 8 | 2024 | 316 | 0.380 |
Why?
| Nutritional Physiological Phenomena | 4 | 2018 | 21 | 0.380 |
Why?
| Hormones | 5 | 2019 | 57 | 0.370 |
Why?
| Extracellular Fluid | 3 | 2006 | 14 | 0.360 |
Why?
| Phospholipids | 2 | 2020 | 55 | 0.360 |
Why?
| Threonine | 3 | 2022 | 15 | 0.360 |
Why?
| Arthroplasty, Replacement, Hip | 2 | 2021 | 263 | 0.350 |
Why?
| Metabolism | 5 | 2020 | 25 | 0.350 |
Why?
| Heart Rate | 3 | 2007 | 307 | 0.350 |
Why?
| Physical Endurance | 3 | 2024 | 31 | 0.350 |
Why?
| Hospitalization | 3 | 2012 | 675 | 0.350 |
Why?
| Nitrogen | 5 | 2022 | 70 | 0.340 |
Why?
| Immobilization | 2 | 2007 | 14 | 0.340 |
Why?
| Cytokines | 4 | 2007 | 606 | 0.340 |
Why?
| Nutritive Value | 3 | 2017 | 28 | 0.330 |
Why?
| Muscular Diseases | 3 | 2006 | 61 | 0.330 |
Why?
| Body Weight | 7 | 2025 | 517 | 0.320 |
Why?
| Cardiac Output | 2 | 2006 | 44 | 0.320 |
Why?
| Biological Transport | 8 | 2013 | 164 | 0.320 |
Why?
| Cattle | 3 | 2024 | 205 | 0.320 |
Why?
| Propanolamines | 2 | 2006 | 14 | 0.320 |
Why?
| Lung Compliance | 2 | 2006 | 9 | 0.310 |
Why?
| Urea | 4 | 2022 | 81 | 0.310 |
Why?
| Models, Animal | 4 | 2016 | 227 | 0.310 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 16 | 0.310 |
Why?
| Musculoskeletal Physiological Phenomena | 2 | 2013 | 7 | 0.310 |
Why?
| Propranolol | 3 | 2006 | 79 | 0.310 |
Why?
| Area Under Curve | 6 | 2008 | 179 | 0.300 |
Why?
| Blood Flow Velocity | 6 | 2007 | 99 | 0.300 |
Why?
| Diet, Carbohydrate-Restricted | 2 | 2018 | 11 | 0.300 |
Why?
| Fibrinogen | 2 | 2005 | 32 | 0.300 |
Why?
| Case-Control Studies | 7 | 2010 | 1155 | 0.300 |
Why?
| Diet, Protein-Restricted | 3 | 2024 | 9 | 0.300 |
Why?
| Protein Kinase C | 1 | 2008 | 71 | 0.300 |
Why?
| Reproducibility of Results | 6 | 2016 | 1199 | 0.300 |
Why?
| Protein Processing, Post-Translational | 1 | 2009 | 156 | 0.300 |
Why?
| Hemoglobins | 2 | 2006 | 109 | 0.300 |
Why?
| Soft Tissue Injuries | 1 | 2008 | 17 | 0.300 |
Why?
| RNA, Transfer, Amino Acyl | 1 | 2007 | 1 | 0.290 |
Why?
| Intracellular Fluid | 2 | 2005 | 12 | 0.290 |
Why?
| Treatment Outcome | 15 | 2020 | 5285 | 0.290 |
Why?
| Absorptiometry, Photon | 5 | 2020 | 156 | 0.290 |
Why?
| Alanine | 3 | 2004 | 43 | 0.280 |
Why?
| Child | 19 | 2022 | 6910 | 0.280 |
Why?
| Acetates | 1 | 2007 | 49 | 0.280 |
Why?
| Insulin, Long-Acting | 1 | 2007 | 1 | 0.280 |
Why?
| Herpesvirus 4, Human | 1 | 2007 | 37 | 0.280 |
Why?
| Intermittent Claudication | 1 | 2007 | 12 | 0.280 |
Why?
| Carbon Dioxide | 1 | 2007 | 95 | 0.270 |
Why?
| Pseudomonas Infections | 2 | 2017 | 48 | 0.270 |
Why?
| Virus Activation | 1 | 2007 | 37 | 0.270 |
Why?
| Peripheral Vascular Diseases | 1 | 2007 | 21 | 0.270 |
Why?
| Acyl Coenzyme A | 2 | 2006 | 8 | 0.270 |
Why?
| Dose-Response Relationship, Drug | 6 | 2009 | 1372 | 0.270 |
Why?
| Muscles | 2 | 2006 | 104 | 0.270 |
Why?
| Malnutrition | 3 | 2021 | 85 | 0.270 |
Why?
| Creatine | 2 | 2016 | 38 | 0.270 |
Why?
| Carnitine | 2 | 2010 | 63 | 0.270 |
Why?
| Dermis | 2 | 2004 | 16 | 0.270 |
Why?
| Hemodynamics | 2 | 2017 | 265 | 0.270 |
Why?
| Mafenide | 1 | 2006 | 1 | 0.260 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2006 | 6 | 0.260 |
Why?
| Valine | 2 | 2003 | 57 | 0.260 |
Why?
| Living Donors | 1 | 2006 | 24 | 0.260 |
Why?
| Military Personnel | 2 | 2019 | 163 | 0.260 |
Why?
| Models, Theoretical | 3 | 2016 | 170 | 0.250 |
Why?
| Mitochondrial Proteins | 3 | 2022 | 88 | 0.250 |
Why?
| Hormone Replacement Therapy | 1 | 2005 | 33 | 0.250 |
Why?
| Fatty Liver | 2 | 2024 | 130 | 0.250 |
Why?
| Shock, Hemorrhagic | 1 | 2005 | 13 | 0.250 |
Why?
| Brain Injuries | 1 | 2007 | 159 | 0.240 |
Why?
| Mitochondrial Dynamics | 3 | 2024 | 21 | 0.240 |
Why?
| Walkers | 1 | 2004 | 2 | 0.240 |
Why?
| Blood Coagulation | 1 | 2005 | 60 | 0.240 |
Why?
| Physical Conditioning, Animal | 2 | 2024 | 57 | 0.230 |
Why?
| PPAR delta | 1 | 2024 | 2 | 0.230 |
Why?
| Dynamins | 1 | 2024 | 7 | 0.230 |
Why?
| Caseins | 1 | 2004 | 78 | 0.230 |
Why?
| Glucose Clamp Technique | 5 | 2009 | 15 | 0.230 |
Why?
| Malonyl Coenzyme A | 2 | 2010 | 7 | 0.230 |
Why?
| Exercise Tolerance | 1 | 2004 | 42 | 0.230 |
Why?
| Hyperandrogenism | 1 | 2024 | 1 | 0.230 |
Why?
| Physical Exertion | 1 | 2004 | 48 | 0.230 |
Why?
| Polycystic Ovary Syndrome | 1 | 2024 | 9 | 0.230 |
Why?
| Dietary Fats | 2 | 2017 | 125 | 0.220 |
Why?
| Child, Preschool | 10 | 2022 | 3943 | 0.220 |
Why?
| Metabolic Clearance Rate | 5 | 2019 | 69 | 0.220 |
Why?
| Egg Proteins | 2 | 2021 | 18 | 0.220 |
Why?
| Cell Division | 4 | 2006 | 291 | 0.220 |
Why?
| Inulin | 1 | 2003 | 9 | 0.220 |
Why?
| Disabled Persons | 1 | 2004 | 75 | 0.220 |
Why?
| Developed Countries | 1 | 2024 | 15 | 0.220 |
Why?
| Disease Models, Animal | 3 | 2019 | 1436 | 0.220 |
Why?
| Injections, Intravenous | 2 | 2014 | 137 | 0.220 |
Why?
| Algorithms | 5 | 2015 | 628 | 0.220 |
Why?
| Glycine | 4 | 2004 | 78 | 0.210 |
Why?
| Nutrition Surveys | 1 | 2024 | 111 | 0.210 |
Why?
| Eukaryotic Initiation Factor-2B | 1 | 2003 | 5 | 0.210 |
Why?
| Accidental Falls | 1 | 2004 | 105 | 0.210 |
Why?
| Reference Values | 6 | 2017 | 307 | 0.210 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2002 | 7 | 0.210 |
Why?
| Pseudomonas aeruginosa | 3 | 2019 | 72 | 0.210 |
Why?
| Carbohydrate Metabolism | 2 | 2019 | 26 | 0.210 |
Why?
| Weightlessness | 1 | 2002 | 12 | 0.210 |
Why?
| Tyrosine | 4 | 2022 | 94 | 0.200 |
Why?
| Vasodilator Agents | 1 | 2003 | 100 | 0.200 |
Why?
| Splanchnic Circulation | 1 | 2002 | 39 | 0.200 |
Why?
| Space Flight | 1 | 2002 | 31 | 0.200 |
Why?
| Polymers | 1 | 2022 | 39 | 0.200 |
Why?
| Diet, High-Fat | 2 | 2024 | 214 | 0.200 |
Why?
| Pulmonary Surfactants | 1 | 2002 | 18 | 0.200 |
Why?
| GTP-Binding Proteins | 1 | 2022 | 91 | 0.200 |
Why?
| Alaska | 2 | 2020 | 26 | 0.200 |
Why?
| Reindeer | 1 | 2021 | 3 | 0.190 |
Why?
| Calorimetry, Indirect | 4 | 2006 | 25 | 0.190 |
Why?
| Autophagy | 2 | 2020 | 170 | 0.190 |
Why?
| Age Factors | 6 | 2017 | 1110 | 0.190 |
Why?
| Injections, Intramuscular | 3 | 2011 | 48 | 0.190 |
Why?
| Mice, Knockout | 1 | 2024 | 844 | 0.190 |
Why?
| Myostatin | 1 | 2021 | 8 | 0.190 |
Why?
| Fasting | 4 | 2020 | 73 | 0.180 |
Why?
| Leptin | 1 | 2022 | 143 | 0.180 |
Why?
| Neoplasms | 1 | 2011 | 1255 | 0.180 |
Why?
| Lysine | 2 | 2017 | 84 | 0.180 |
Why?
| Proteolipids | 1 | 2021 | 10 | 0.180 |
Why?
| Severity of Illness Index | 4 | 2017 | 978 | 0.180 |
Why?
| Glycogenolysis | 1 | 2020 | 10 | 0.180 |
Why?
| Health Status | 2 | 2016 | 299 | 0.180 |
Why?
| Plant Proteins | 1 | 2021 | 68 | 0.180 |
Why?
| Prospective Studies | 5 | 2017 | 2378 | 0.180 |
Why?
| Palmitic Acid | 4 | 2005 | 22 | 0.180 |
Why?
| Random Allocation | 2 | 2015 | 289 | 0.180 |
Why?
| Femoral Artery | 3 | 2007 | 106 | 0.180 |
Why?
| Hyperphagia | 1 | 2020 | 10 | 0.180 |
Why?
| Postoperative Care | 1 | 2021 | 104 | 0.180 |
Why?
| Analysis of Variance | 6 | 2009 | 552 | 0.170 |
Why?
| Breast Feeding | 1 | 2022 | 189 | 0.170 |
Why?
| Hypoglycemia | 1 | 2020 | 55 | 0.170 |
Why?
| Fatty Acids, Omega-3 | 1 | 2020 | 28 | 0.170 |
Why?
| Fatty Liver, Alcoholic | 1 | 2020 | 7 | 0.170 |
Why?
| RNA, Messenger | 2 | 2022 | 1089 | 0.170 |
Why?
| Enteral Nutrition | 4 | 2006 | 150 | 0.170 |
Why?
| Preoperative Care | 1 | 2021 | 169 | 0.170 |
Why?
| Health | 2 | 2012 | 23 | 0.160 |
Why?
| United States | 5 | 2024 | 4955 | 0.160 |
Why?
| Fruit | 1 | 2020 | 119 | 0.160 |
Why?
| Carcinoma, Hepatocellular | 1 | 2022 | 196 | 0.160 |
Why?
| Mouth | 1 | 2019 | 32 | 0.160 |
Why?
| Hindlimb | 3 | 2008 | 30 | 0.160 |
Why?
| Molecular Probe Techniques | 1 | 2019 | 8 | 0.160 |
Why?
| Military Medicine | 1 | 2019 | 22 | 0.160 |
Why?
| Radioisotope Dilution Technique | 3 | 2004 | 12 | 0.160 |
Why?
| Water | 1 | 2019 | 76 | 0.160 |
Why?
| Evaluation Studies as Topic | 1 | 2019 | 107 | 0.160 |
Why?
| Palmitoylcarnitine | 2 | 2011 | 7 | 0.160 |
Why?
| Intestinal Absorption | 1 | 2019 | 47 | 0.160 |
Why?
| Altitude Sickness | 2 | 2012 | 7 | 0.160 |
Why?
| Proteome | 1 | 2020 | 169 | 0.160 |
Why?
| Jejunum | 1 | 2019 | 54 | 0.160 |
Why?
| Hypoalbuminemia | 1 | 2018 | 4 | 0.160 |
Why?
| Basal Metabolism | 3 | 2020 | 32 | 0.150 |
Why?
| Occupational Diseases | 1 | 2019 | 82 | 0.150 |
Why?
| Lung | 1 | 2002 | 504 | 0.150 |
Why?
| Liver Neoplasms | 1 | 2022 | 327 | 0.150 |
Why?
| Cholesterol | 3 | 2013 | 150 | 0.150 |
Why?
| Inflammation | 4 | 2018 | 610 | 0.150 |
Why?
| Alcohol Drinking | 1 | 2020 | 227 | 0.150 |
Why?
| Oxandrolone | 2 | 2011 | 10 | 0.150 |
Why?
| Intestinal Mucosa | 1 | 2019 | 216 | 0.150 |
Why?
| Breakfast | 1 | 2017 | 15 | 0.140 |
Why?
| Lower Extremity | 2 | 2009 | 92 | 0.140 |
Why?
| Gastrointestinal Tract | 1 | 2018 | 103 | 0.140 |
Why?
| Oxygen Consumption | 6 | 2019 | 191 | 0.140 |
Why?
| Injections, Intradermal | 2 | 2007 | 13 | 0.140 |
Why?
| Circadian Rhythm | 1 | 2017 | 90 | 0.140 |
Why?
| Hypertension, Pulmonary | 2 | 2012 | 124 | 0.140 |
Why?
| Quadriceps Muscle | 1 | 2017 | 47 | 0.140 |
Why?
| Nutrition Assessment | 1 | 2017 | 64 | 0.130 |
Why?
| Sleep Apnea, Obstructive | 1 | 2017 | 67 | 0.130 |
Why?
| Endpoint Determination | 1 | 2016 | 26 | 0.130 |
Why?
| Mice | 6 | 2024 | 5687 | 0.130 |
Why?
| Athletic Performance | 1 | 2016 | 31 | 0.130 |
Why?
| Egg Proteins, Dietary | 1 | 2016 | 2 | 0.130 |
Why?
| Food Quality | 1 | 2016 | 2 | 0.130 |
Why?
| Physical Fitness | 2 | 2014 | 60 | 0.130 |
Why?
| Chromatography, Liquid | 2 | 2008 | 231 | 0.130 |
Why?
| Rest | 2 | 2007 | 63 | 0.130 |
Why?
| Chronic Disease | 4 | 2017 | 574 | 0.130 |
Why?
| Hyperemia | 1 | 2015 | 18 | 0.130 |
Why?
| Forearm | 1 | 2015 | 28 | 0.130 |
Why?
| Magnetic Resonance Spectroscopy | 2 | 2008 | 244 | 0.120 |
Why?
| Tissue Donors | 2 | 2007 | 121 | 0.120 |
Why?
| Constriction | 2 | 2007 | 9 | 0.120 |
Why?
| Microdialysis | 2 | 2005 | 19 | 0.120 |
Why?
| Waist Circumference | 1 | 2015 | 19 | 0.120 |
Why?
| Capillaries | 2 | 2007 | 52 | 0.120 |
Why?
| Hand Strength | 1 | 2015 | 22 | 0.120 |
Why?
| Cross-Sectional Studies | 3 | 2008 | 1608 | 0.120 |
Why?
| Femoral Vein | 2 | 2005 | 40 | 0.110 |
Why?
| NF-kappa B | 2 | 2007 | 315 | 0.110 |
Why?
| Radioactive Tracers | 2 | 2019 | 9 | 0.110 |
Why?
| Logistic Models | 2 | 2015 | 899 | 0.110 |
Why?
| Endothelium, Vascular | 1 | 2015 | 251 | 0.110 |
Why?
| Weight Gain | 2 | 2022 | 237 | 0.110 |
Why?
| Proline | 2 | 2004 | 30 | 0.110 |
Why?
| Exercise Test | 3 | 2019 | 131 | 0.110 |
Why?
| Motor Activity | 3 | 2010 | 225 | 0.110 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 193 | 0.110 |
Why?
| Pulmonary Edema | 2 | 2004 | 20 | 0.110 |
Why?
| Walking | 1 | 2014 | 100 | 0.110 |
Why?
| Carbohydrates | 2 | 2019 | 38 | 0.100 |
Why?
| Risk Assessment | 4 | 2017 | 1269 | 0.100 |
Why?
| Evidence-Based Medicine | 2 | 2012 | 253 | 0.100 |
Why?
| Extremities | 1 | 2013 | 30 | 0.100 |
Why?
| Oxygen | 2 | 2006 | 323 | 0.100 |
Why?
| Tissue and Organ Procurement | 2 | 2004 | 50 | 0.100 |
Why?
| Arginase | 1 | 2012 | 37 | 0.100 |
Why?
| Follow-Up Studies | 4 | 2017 | 2242 | 0.100 |
Why?
| Cystic Fibrosis | 2 | 2013 | 147 | 0.100 |
Why?
| Altitude | 1 | 2012 | 16 | 0.100 |
Why?
| Nitric Oxide Synthase | 2 | 2012 | 74 | 0.100 |
Why?
| Guidelines as Topic | 1 | 2012 | 109 | 0.100 |
Why?
| Metabolic Diseases | 1 | 2012 | 44 | 0.100 |
Why?
| Organ Size | 1 | 2012 | 225 | 0.100 |
Why?
| Healthcare Disparities | 1 | 2015 | 281 | 0.090 |
Why?
| Cell Line | 2 | 2004 | 988 | 0.090 |
Why?
| Glucose Tolerance Test | 3 | 2010 | 58 | 0.090 |
Why?
| Liver Transplantation | 2 | 2004 | 154 | 0.090 |
Why?
| Parenteral Nutrition | 2 | 2016 | 28 | 0.090 |
Why?
| Pulmonary Artery | 1 | 2012 | 154 | 0.090 |
Why?
| Breath Tests | 2 | 2007 | 39 | 0.080 |
Why?
| Cushing Syndrome | 1 | 2009 | 11 | 0.080 |
Why?
| Texas | 2 | 2007 | 142 | 0.080 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2022 | 573 | 0.080 |
Why?
| Blood Pressure | 2 | 2017 | 531 | 0.080 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 135 | 0.080 |
Why?
| Insulin-Like Growth Factor I | 2 | 2007 | 136 | 0.080 |
Why?
| Antiphospholipid Syndrome | 1 | 2009 | 10 | 0.080 |
Why?
| Cholesterol, VLDL | 1 | 2008 | 3 | 0.080 |
Why?
| Polysomnography | 2 | 2020 | 71 | 0.080 |
Why?
| Body Surface Area | 2 | 2006 | 26 | 0.080 |
Why?
| Institutionalization | 1 | 2008 | 12 | 0.080 |
Why?
| Cachexia | 1 | 2008 | 25 | 0.080 |
Why?
| Satiation | 1 | 2008 | 8 | 0.080 |
Why?
| Kidney Function Tests | 1 | 2008 | 51 | 0.070 |
Why?
| Muscle Strength Dynamometer | 1 | 2008 | 12 | 0.070 |
Why?
| Gene Expression Regulation | 4 | 2010 | 955 | 0.070 |
Why?
| Fontan Procedure | 1 | 2009 | 70 | 0.070 |
Why?
| Linear Models | 2 | 2009 | 279 | 0.070 |
Why?
| Parenteral Nutrition Solutions | 2 | 2004 | 8 | 0.070 |
Why?
| Citric Acid Cycle | 1 | 2007 | 18 | 0.070 |
Why?
| Solutions | 2 | 2004 | 25 | 0.070 |
Why?
| RNA, Transfer | 1 | 2007 | 15 | 0.070 |
Why?
| Sodium Bicarbonate | 1 | 2007 | 9 | 0.070 |
Why?
| Ketoconazole | 1 | 2007 | 10 | 0.070 |
Why?
| Sleep | 2 | 2020 | 184 | 0.070 |
Why?
| Electrolytes | 2 | 2004 | 27 | 0.070 |
Why?
| Space Simulation | 1 | 2007 | 2 | 0.070 |
Why?
| Placebos | 2 | 2004 | 87 | 0.070 |
Why?
| Hypoplastic Left Heart Syndrome | 1 | 2009 | 95 | 0.070 |
Why?
| Mice, Inbred C57BL | 2 | 2024 | 1808 | 0.070 |
Why?
| Adenosine Triphosphate | 1 | 2008 | 232 | 0.070 |
Why?
| Tandem Mass Spectrometry | 1 | 2008 | 238 | 0.070 |
Why?
| Saliva | 1 | 2007 | 55 | 0.070 |
Why?
| Gait | 1 | 2008 | 89 | 0.070 |
Why?
| Acute Disease | 2 | 2019 | 373 | 0.070 |
Why?
| Virus Latency | 1 | 2007 | 52 | 0.070 |
Why?
| Trauma Severity Indices | 1 | 2007 | 48 | 0.070 |
Why?
| Sex Factors | 2 | 2020 | 711 | 0.070 |
Why?
| RNA | 1 | 2007 | 163 | 0.070 |
Why?
| Cell Compartmentation | 1 | 2006 | 10 | 0.070 |
Why?
| Waiting Lists | 2 | 2004 | 59 | 0.070 |
Why?
| Risk Factors | 4 | 2019 | 3723 | 0.070 |
Why?
| Siloxanes | 1 | 2006 | 2 | 0.070 |
Why?
| Styrenes | 1 | 2006 | 2 | 0.070 |
Why?
| Occlusive Dressings | 1 | 2006 | 6 | 0.070 |
Why?
| Osmolar Concentration | 2 | 2003 | 62 | 0.070 |
Why?
| APACHE | 1 | 2006 | 23 | 0.070 |
Why?
| Administration, Topical | 1 | 2006 | 57 | 0.070 |
Why?
| Dermatologic Surgical Procedures | 1 | 2006 | 34 | 0.060 |
Why?
| Bandages | 1 | 2006 | 25 | 0.060 |
Why?
| Hepatomegaly | 1 | 2006 | 7 | 0.060 |
Why?
| Resource Allocation | 2 | 2004 | 16 | 0.060 |
Why?
| Methods | 1 | 2005 | 55 | 0.060 |
Why?
| Anti-Infective Agents, Local | 1 | 2006 | 27 | 0.060 |
Why?
| Carbohydrate Sequence | 1 | 2005 | 11 | 0.060 |
Why?
| Creatinine | 1 | 2006 | 145 | 0.060 |
Why?
| Anti-Inflammatory Agents | 1 | 2007 | 163 | 0.060 |
Why?
| Injury Severity Score | 1 | 2006 | 164 | 0.060 |
Why?
| Reference Standards | 1 | 2005 | 52 | 0.060 |
Why?
| Infusions, Intra-Arterial | 1 | 2005 | 15 | 0.060 |
Why?
| Life Style | 1 | 2006 | 144 | 0.060 |
Why?
| Pressure Ulcer | 1 | 2005 | 15 | 0.060 |
Why?
| Fibrinolysis | 1 | 2005 | 5 | 0.060 |
Why?
| Body Water | 1 | 2005 | 24 | 0.060 |
Why?
| Milk | 1 | 2006 | 80 | 0.060 |
Why?
| Arteries | 2 | 2004 | 91 | 0.060 |
Why?
| Blood Coagulation Tests | 1 | 2005 | 20 | 0.060 |
Why?
| Hematocrit | 1 | 2005 | 43 | 0.060 |
Why?
| Stress, Psychological | 1 | 2007 | 266 | 0.060 |
Why?
| Fluorocarbons | 1 | 2005 | 58 | 0.060 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 468 | 0.060 |
Why?
| Ecchymosis | 1 | 2004 | 8 | 0.060 |
Why?
| Osteoporosis | 1 | 2006 | 156 | 0.060 |
Why?
| Myocardial Infarction | 1 | 2009 | 403 | 0.060 |
Why?
| Signal Transduction | 3 | 2020 | 1624 | 0.060 |
Why?
| Blood Specimen Collection | 1 | 2004 | 35 | 0.060 |
Why?
| Biological Transport, Active | 1 | 2004 | 30 | 0.060 |
Why?
| Muscle Fatigue | 1 | 2004 | 14 | 0.060 |
Why?
| Amino Acid Sequence | 1 | 2005 | 574 | 0.060 |
Why?
| Hematoma | 1 | 2004 | 64 | 0.060 |
Why?
| Locomotion | 1 | 2004 | 84 | 0.060 |
Why?
| Culture Media | 1 | 2004 | 93 | 0.060 |
Why?
| Molecular Sequence Data | 1 | 2005 | 778 | 0.060 |
Why?
| Biopsy, Needle | 1 | 2004 | 178 | 0.060 |
Why?
| Catheterization | 1 | 2004 | 101 | 0.060 |
Why?
| Interleukin-18 | 1 | 2024 | 27 | 0.060 |
Why?
| Health Care Rationing | 1 | 2004 | 11 | 0.060 |
Why?
| Respiratory Function Tests | 1 | 2004 | 86 | 0.060 |
Why?
| Albumins | 1 | 2004 | 31 | 0.060 |
Why?
| Iontophoresis | 1 | 2003 | 15 | 0.060 |
Why?
| Physical Education and Training | 1 | 2004 | 24 | 0.060 |
Why?
| Pilocarpine | 1 | 2003 | 25 | 0.060 |
Why?
| Amino Acid Transport Systems | 1 | 2003 | 5 | 0.060 |
Why?
| Adaptation, Physiological | 1 | 2004 | 93 | 0.050 |
Why?
| Equipment Design | 1 | 2004 | 289 | 0.050 |
Why?
| RNA, Ribosomal, 16S | 1 | 2024 | 112 | 0.050 |
Why?
| Cell Count | 1 | 2004 | 150 | 0.050 |
Why?
| Glutamic Acid | 1 | 2004 | 113 | 0.050 |
Why?
| Injections, Intra-Arterial | 1 | 2003 | 13 | 0.050 |
Why?
| Nitric Oxide Donors | 1 | 2003 | 11 | 0.050 |
Why?
| Nitroprusside | 1 | 2003 | 11 | 0.050 |
Why?
| Obesity, Morbid | 1 | 2004 | 78 | 0.050 |
Why?
| Regression Analysis | 1 | 2004 | 382 | 0.050 |
Why?
| Cough | 1 | 2003 | 54 | 0.050 |
Why?
| Computer Simulation | 1 | 2004 | 279 | 0.050 |
Why?
| Ovarian Neoplasms | 1 | 2007 | 450 | 0.050 |
Why?
| Time | 1 | 2003 | 28 | 0.050 |
Why?
| Blood Circulation | 1 | 2003 | 15 | 0.050 |
Why?
| Coloring Agents | 1 | 2003 | 66 | 0.050 |
Why?
| Carbazoles | 1 | 2003 | 16 | 0.050 |
Why?
| Hydroxyproline | 1 | 2003 | 19 | 0.050 |
Why?
| Ventricular Dysfunction | 1 | 2003 | 10 | 0.050 |
Why?
| Indocyanine Green | 1 | 2003 | 34 | 0.050 |
Why?
| Body Constitution | 1 | 2002 | 12 | 0.050 |
Why?
| Weightlessness Countermeasures | 1 | 2002 | 2 | 0.050 |
Why?
| Transposition of Great Vessels | 1 | 2003 | 25 | 0.050 |
Why?
| Drug Combinations | 1 | 2003 | 127 | 0.050 |
Why?
| Cell Membrane | 1 | 2003 | 246 | 0.050 |
Why?
| Kidney Diseases | 1 | 2005 | 213 | 0.050 |
Why?
| Fish Oils | 1 | 2002 | 13 | 0.050 |
Why?
| Linoleic Acid | 1 | 2002 | 14 | 0.050 |
Why?
| Phosphatidylcholines | 1 | 2002 | 24 | 0.050 |
Why?
| Blood Proteins | 1 | 2023 | 84 | 0.050 |
Why?
| Ear | 1 | 2002 | 17 | 0.050 |
Why?
| Microspheres | 1 | 2002 | 27 | 0.050 |
Why?
| Endotoxins | 1 | 2002 | 31 | 0.050 |
Why?
| Fat Emulsions, Intravenous | 1 | 2002 | 13 | 0.050 |
Why?
| Leukocyte Count | 1 | 2002 | 69 | 0.050 |
Why?
| Lactates | 1 | 2022 | 30 | 0.050 |
Why?
| Communicable Disease Control | 1 | 2022 | 35 | 0.050 |
Why?
| Ribosomal Proteins | 1 | 2022 | 24 | 0.050 |
Why?
| Carotid Arteries | 1 | 2002 | 84 | 0.050 |
Why?
| Drug Synergism | 1 | 2002 | 151 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2004 | 861 | 0.050 |
Why?
| Thinness | 2 | 2016 | 44 | 0.050 |
Why?
| Neutrophils | 1 | 2002 | 145 | 0.050 |
Why?
| Cell Cycle Proteins | 1 | 2022 | 161 | 0.050 |
Why?
| Gene Expression | 1 | 2003 | 610 | 0.040 |
Why?
| Food | 1 | 2020 | 66 | 0.040 |
Why?
| Orthopedic Procedures | 1 | 2021 | 70 | 0.040 |
Why?
| Ceramides | 1 | 2020 | 31 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2022 | 222 | 0.040 |
Why?
| Dexamethasone | 1 | 2022 | 432 | 0.040 |
Why?
| Protein Kinases | 1 | 2020 | 71 | 0.040 |
Why?
| T-Lymphocytes | 1 | 2022 | 325 | 0.040 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 156 | 0.040 |
Why?
| Occupational Health | 1 | 2019 | 66 | 0.040 |
Why?
| Capillary Permeability | 1 | 2018 | 34 | 0.040 |
Why?
| Rats, Zucker | 2 | 2010 | 68 | 0.040 |
Why?
| Apoptosis | 1 | 2003 | 1097 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2004 | 519 | 0.040 |
Why?
| Body Weights and Measures | 1 | 2017 | 17 | 0.040 |
Why?
| Artifacts | 1 | 2018 | 55 | 0.040 |
Why?
| Hunger | 1 | 2017 | 15 | 0.040 |
Why?
| Animal Structures | 1 | 2017 | 3 | 0.040 |
Why?
| Clinical Chemistry Tests | 1 | 2017 | 3 | 0.040 |
Why?
| Withholding Treatment | 1 | 2017 | 19 | 0.040 |
Why?
| Blood Gas Analysis | 1 | 2017 | 30 | 0.040 |
Why?
| Pandemics | 1 | 2022 | 562 | 0.040 |
Why?
| Pilot Projects | 1 | 2020 | 699 | 0.040 |
Why?
| Indicator Dilution Techniques | 1 | 2017 | 10 | 0.030 |
Why?
| Venae Cavae | 1 | 2017 | 10 | 0.030 |
Why?
| Crosses, Genetic | 1 | 2017 | 32 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2017 | 111 | 0.030 |
Why?
| Sus scrofa | 1 | 2017 | 37 | 0.030 |
Why?
| Continuous Positive Airway Pressure | 1 | 2017 | 63 | 0.030 |
Why?
| Glycogen | 2 | 2010 | 42 | 0.030 |
Why?
| Caffeine | 1 | 2016 | 64 | 0.030 |
Why?
| Catheterization, Central Venous | 1 | 2017 | 85 | 0.030 |
Why?
| Oxidative Stress | 1 | 2020 | 772 | 0.030 |
Why?
| Research Design | 1 | 2017 | 353 | 0.030 |
Why?
| Gastrointestinal Diseases | 1 | 2016 | 125 | 0.030 |
Why?
| Pregnancy | 1 | 2022 | 2451 | 0.030 |
Why?
| Multienzyme Complexes | 2 | 2006 | 36 | 0.030 |
Why?
| Cardiac Catheterization | 2 | 2009 | 223 | 0.030 |
Why?
| Diagnostic Imaging | 1 | 2016 | 181 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2017 | 930 | 0.030 |
Why?
| Postoperative Complications | 1 | 2021 | 1033 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2015 | 415 | 0.030 |
Why?
| Octreotide | 1 | 2013 | 9 | 0.030 |
Why?
| Subcutaneous Fat, Abdominal | 1 | 2013 | 6 | 0.030 |
Why?
| Quality of Health Care | 1 | 2015 | 184 | 0.030 |
Why?
| Intra-Abdominal Fat | 1 | 2013 | 21 | 0.030 |
Why?
| Ubiquitin | 2 | 2003 | 45 | 0.030 |
Why?
| Medicare | 1 | 2015 | 247 | 0.030 |
Why?
| Health Status Disparities | 1 | 2015 | 202 | 0.030 |
Why?
| Colorado | 1 | 2012 | 21 | 0.020 |
Why?
| Rats | 2 | 2010 | 3292 | 0.020 |
Why?
| Age of Onset | 1 | 2012 | 108 | 0.020 |
Why?
| Endothelial Cells | 1 | 2012 | 258 | 0.020 |
Why?
| Acetyl-CoA Carboxylase | 1 | 2010 | 13 | 0.020 |
Why?
| Amino-Acid N-Acetyltransferase | 1 | 2010 | 2 | 0.020 |
Why?
| Sciatic Nerve | 1 | 2010 | 24 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 234 | 0.020 |
Why?
| Clinical Protocols | 1 | 2010 | 110 | 0.020 |
Why?
| Retrospective Studies | 2 | 2012 | 6264 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 370 | 0.020 |
Why?
| Protein-Energy Malnutrition | 1 | 2009 | 19 | 0.020 |
Why?
| Chest Pain | 1 | 2009 | 55 | 0.020 |
Why?
| Down-Regulation | 1 | 2010 | 340 | 0.020 |
Why?
| Cardiac Surgical Procedures | 1 | 2012 | 314 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2011 | 735 | 0.020 |
Why?
| Movement | 1 | 2008 | 82 | 0.020 |
Why?
| Thermogenesis | 1 | 2008 | 24 | 0.020 |
Why?
| Patient Discharge | 1 | 2010 | 321 | 0.020 |
Why?
| Blood Chemical Analysis | 1 | 2007 | 28 | 0.020 |
Why?
| Electrocardiography | 1 | 2009 | 263 | 0.020 |
Why?
| Diglycerides | 1 | 2006 | 9 | 0.020 |
Why?
| Coronary Angiography | 1 | 2009 | 359 | 0.020 |
Why?
| Lipolysis | 1 | 2006 | 11 | 0.020 |
Why?
| AMP-Activated Protein Kinases | 1 | 2006 | 28 | 0.020 |
Why?
| Aerobiosis | 1 | 2006 | 14 | 0.020 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2006 | 155 | 0.020 |
Why?
| Cohort Studies | 1 | 2010 | 1452 | 0.020 |
Why?
| Anticoagulants | 1 | 2009 | 256 | 0.020 |
Why?
| Hematinics | 1 | 2005 | 13 | 0.020 |
Why?
| Phosphorylation | 1 | 2006 | 525 | 0.020 |
Why?
| Surgical Procedures, Operative | 1 | 2006 | 67 | 0.010 |
Why?
| Erythropoietin | 1 | 2005 | 50 | 0.010 |
Why?
| Glomerular Filtration Rate | 1 | 2005 | 119 | 0.010 |
Why?
| Drug Utilization | 1 | 2005 | 76 | 0.010 |
Why?
| Mice, Inbred ICR | 1 | 2004 | 23 | 0.010 |
Why?
| Hindlimb Suspension | 1 | 2004 | 37 | 0.010 |
Why?
| Gastric Bypass | 1 | 2004 | 20 | 0.010 |
Why?
| Diaphragm | 1 | 2004 | 31 | 0.010 |
Why?
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2003 | 2 | 0.010 |
Why?
| Veins | 1 | 2004 | 73 | 0.010 |
Why?
| Bronchiectasis | 1 | 2003 | 9 | 0.010 |
Why?
| Complement System Proteins | 1 | 2003 | 31 | 0.010 |
Why?
| Forced Expiratory Volume | 1 | 2003 | 44 | 0.010 |
Why?
| Acidosis | 1 | 2003 | 36 | 0.010 |
Why?
| Caspase 3 | 1 | 2003 | 93 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2005 | 476 | 0.010 |
Why?
| Immunoglobulin E | 1 | 2003 | 91 | 0.010 |
Why?
| Extracellular Space | 1 | 2003 | 40 | 0.010 |
Why?
| Food Additives | 1 | 2003 | 7 | 0.010 |
Why?
| Infant | 1 | 2012 | 3629 | 0.010 |
Why?
| Protein Array Analysis | 1 | 2003 | 23 | 0.010 |
Why?
| Organic Chemicals | 1 | 2003 | 14 | 0.010 |
Why?
| Caspases | 1 | 2003 | 103 | 0.010 |
Why?
| Graft Survival | 1 | 2004 | 159 | 0.010 |
Why?
| Wound Infection | 1 | 2003 | 27 | 0.010 |
Why?
| Cysteine Endopeptidases | 1 | 2003 | 67 | 0.010 |
Why?
| Comorbidity | 1 | 2004 | 623 | 0.010 |
Why?
| Diuresis | 1 | 2002 | 10 | 0.010 |
Why?
| Patient Selection | 1 | 2004 | 259 | 0.010 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2003 | 116 | 0.010 |
Why?
| Stroke Volume | 1 | 2003 | 141 | 0.010 |
Why?
| Recurrence | 1 | 2003 | 659 | 0.010 |
Why?
| Norepinephrine | 1 | 2002 | 114 | 0.010 |
Why?
| Receptors, Androgen | 1 | 2002 | 45 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 405 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2003 | 641 | 0.010 |
Why?
| Health Policy | 1 | 2002 | 146 | 0.010 |
Why?
| Prostate | 1 | 2002 | 114 | 0.010 |
Why?
| Incidence | 1 | 2004 | 1032 | 0.010 |
Why?
| Survival Analysis | 1 | 2002 | 661 | 0.010 |
Why?
| Blotting, Western | 1 | 2002 | 578 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2003 | 1033 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1025 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2003 | 1169 | 0.010 |
Why?
|
|
Wolfe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|